Med Business World

Your source for healthcare business

Geir Lund

COAST GUARD VETERAN WALKING ACROSS AMERICA TO RAISE AWARENESS FOR MENTAL HEALTH

The Coast Guard Foundation, a non-profit organization committed to strengthening the Coast Guard community and service by supporting members and families, announced that Robert Luna, a retired Coast Guard veteran and chief petty officer, is walking from Alabama to California to raise awareness for mental…

Alafair Biosciences Awarded Synthetic Implantable Products Agreement with Premier, Inc. for VersaWrap® Hydrogel Sheet

Alafair Biosciences, Inc., is revolutionizing soft tissue protection with innovative hydrogel medical devices, today announced that its flagship product, VersaWrap Hydrogel Sheet (VersaWrap), has been awarded a national group purchasing agreement with Premier, Inc. Effective July 1, 2024, the new agreement allows…

Medical Dialogues Receives Prestigious AACI Medical Content Certification

Medical Dialogues, the leading digital medical news and information platform in India, has been awarded the prestigious @TRUST Certification by the American Certification Commission International (AACI), recognising its commitment to maintaining the highest editorial standards in medical content publishing. The…

Xylyx Bio announces exclusive license agreement with Vanderbilt University for donor organ rehabilitation asset

Xylyx Bio, a regenerative medicine company developing innovative solutions for tissue and organ repair, today announced entry into an exclusive license agreement with Vanderbilt University for the rights to a xenogeneic cross-circulation platform that restores damaged donor organs to transplant condition. The…

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Hyundai Bioscience announced on April 25th that its clinical development plan of oral “Niclosamide Metabolic Anticancer Drug” targeting cancer patients with intractable cancer caused by p53 gene mutations. Mutations in the p53 gene occur in almost all cancer types and cause intractable…

PHAXIAM Therapeutics announces enrolment of the first patient in the phase 1 study for the treatment of endocarditis infections caused by Staphylococcus aureus

PHAXIAM Therapeutics (Nasdaq & Euronext: FR0011471135), today announces the enrolment of the 1st patient in the phase 1 clinical study in endocarditis infection caused by Staphylococcus aureus (S. aureus). Endocarditis is an infection of the endocardium (inner lining of the…

Novel research leverages AI to identify dogs at higher risk for cancer

A novel canine cancer study funded by Morris Animal Foundation and the Golden Retriever Foundation® is leveraging artificial intelligence to pioneer an innovative approach to early detection and prevention for dogs suspectable to developing diffuse large B-cell lymphoma, the most common form of…

Revive Drip’s Expert IV Nurses Bring Alternative Wellness Solutions to the Greater Puget Sound Area

Revive Drip, a leading mobile intravenous therapy (IV) company providing customized hydration and immune-boosting therapy throughout the Puget Sound, announced today the opening of the company’s brick-and-mortar clinic in Gig Harbor, Washington. The company’s expansion marks an exciting milestone for…

Scilex Holding Company Provides Responses to Product Composition Questions Related to its ELYXYB® Patent in Canada for a New Drug Submission Under Review by Health Canada for the Approval of ELYXYB® for Acute Treatment of Migraine With or Without Aura in Canada

Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that it has responded to questions on the…

Recce Pharmaceuticals Doses Next Cohort in Phase I/II Trial of RECCE® 327 for Urinary Tract Infections and Urosepsis

Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), (the Company), the Company developing a new class of synthetic anti-infectives, today announced it dosed the next cohort of healthy subjects at 3,000mg within a fast infusion rate of 20-minutes in a Phase…